Mipomersen Sodium

Mipomersen sodium is an oligonucleotide inhibitor of apo B-100 synthesis. ApoB is the principal apolipoprotein of LDL and its metabolic precursor, very low density lipoprotei (VLDL). Mipomersen inhibits synthesis of apoB by sequence-specific binding to its messenger ribonucleic acid (mRNA) resulting in degradation of the mRNA through enzyme-mediated pathways or disruption of mRNA function through binding alone. It is used as adjunct to lipid lowering medications and diet to reduced low density lipoprotein cholestrol(LDL C) Apolipoprotein B, total cholestrol(TC) and non high density lipoproteincholestrol (Non HDL C) in patient with Homozygous Familial HyperCholesterolemia(HOFH)

Brands
Adult Dose
Neonatal
Paedriatic
Characteristics
. It is of Synthetic origin and belongs to phosphorothioate oligonucleotide sodium salt. It belongs to Lipid lowering agents pharmacological group on the basis of mechanism of action. The Molecular Weight of Mipomersen Sodium is 7594.90.
Contraindications
Mipomersen Sodium
Effects
The symptomatic adverse reactions produced by Mipomersen Sodium are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Nausea, Injection site reactions, Flu like symptoms, elevation in serum transaminases.
Indications
Mipomersen Sodium is primarily indicated in conditions like Homozygous familial hypercholesterolemia.
Interactions
No data regarding the interactions of Mipomersen Sodium was found.
Interfrence
Risks
Drug should not be given to Paediatrics, Cardiac / Hypertensive Patients, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Injection Protect from Sunlight and Heat.
Warnings
De to risk of hepatic toxicity, before beginning treatment, measure transaminases (ALT, AST), alkaline phosphatase, and total bilirubin . injection site reactions like erythema, pain, tenderness, pruritus and local swelling, Flu-like symptoms such as influenza like illness, pyrexia, chills, myalgia, arthralgia, malaise or fatigue, which typically occur within 2 days after an injection,
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.